FFA
TLX

Farther Finance Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Farther Finance Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161 Buy
14
+5
+56% +$51 ﹤0.01% 5749
2026
Q1 		$83 Hold
9
– – ﹤0.01% 5532
2025
Q4 		$67 Hold
9
– – ﹤0.01% 5332
2025
Q3 		$86 Buy
+9
New +$110 ﹤0.01% 4832

Other funds holding TLX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Farther Finance Advisors's TLX Position: Q2 2026 in Review

Farther Finance Advisors increased its Telix Pharmaceuticals (TLX) stake by 56% in Q2 2026, buying an estimated $51 and bringing the position to 14 shares worth $161. The position accounts for ﹤0.01% of the portfolio, ranked #5749.

Farther Finance Advisors first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Farther Finance Advisors held 14 shares of Telix Pharmaceuticals worth $161 as of Q2 2026.
  • Farther Finance Advisors bought 5 Telix Pharmaceuticals shares in Q2 2026, an estimated $51.
  • Telix Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5749 holding.
  • Farther Finance Advisors first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.